AbbVie, Denmark’s Genmab enter nearly $4B cancer immunotherapy partnership
The deal, which includes a hefty $750 million upfront payment to Genmab, focuses on bispecific antibodies and also a drug discovery research partnership.
Drugmakers’ financial fortunes during Covid-19 may hinge on their product mix
Analyst reports over the past few weeks have looked into what effects the Covid-19 pandemic could have on drugmakers' sales, examining multiple factors. But virtual launches and telemedicine could mitigate some market challenges.
What Are Healthcare Organizations Getting Wrong about Email Security?
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
AbbVie, Roche leukemia drug successful in Phase III confirmatory study
The companies said Venclexta extended overall survival in untreated acute myeloid leukemia patients when combined with Bristol-Myers Squibb's Vidaza. A prior Phase III confirmatory trial, combining the drug with low-dose cytarabine, failed.
AbbVie’s HIV drug fails Covid-19 trial in China, but a Fujifilm flu drug may have efficacy
Study results showed AbbVie's Kaletra did no better than standard treatment. Meanwhile, a generic version of Fujifilm's Avigan, which the NIH said it is considering, showed signs of efficacy, though some regulators are skeptical of the flu drug.
Coronavirus drugs, vaccines could come sooner than projected, experts say
A greater willingness to embrace new technologies has made it easier to develop vaccines against the 2019-nCoV virus, while newer drugs have also shown signs of efficacy, experts said. More than 17,000 were confirmed infected worldwide as of Monday, the WHO reported.
Allergan to divest two drugs to satisfy regulators in $63B acquisition by AbbVie
One of the buyers, AstraZeneca, said separately that it would divest several hypertension drugs as it shifts the focus of its pipeline to newer medicines.
Solving Healthcare’s Provider Data Problem Starts with Interoperability
Break down the silos. Take control of your provider data.
Geopolitical, economic concerns unlikely to stem pharma, life science industry capital deployment, report finds
Deal value for the third quarter fell sharply from what it was in the first and second quarter, but that was due to the absence of the large acquisitions that took place earlier this year rather than an overall downward trend.
Drug price increases without supporting evidence raised spending by $5.1B, ICER says
The nonprofit called out seven drugmakers in its report on "unsupported price increases" Tuesday. Drugmakers criticized the organization's methodology in response.
Senators urge greater FTC scrutiny over large biopharma mergers
Nine senators sent a letter to FTC Chairman Joseph Simons urging greater scrutiny over like the one between BMS and Celgene, expressing concern over antitrust issues, innovation and drug pricing.
FDA issues warning about hepatitis C drug as dozens of patients experience worsening liver function
The agency warned against use of AbbVie's Mavyret, Gilead Sciences' Vesovi and Merck's Zepatier in patients with moderate to severe liver disease amid reports of 63 patients with liver decompensation, with some cases being fatal.
presented by
A Path to Healing: Discovering Arizona’s PTSD Treatment Centers
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
FDA approves AbbVie rheumatoid arthritis drug
Reuters reported that the drug, Rinvoq, will carry a list price of $59,000 per year. AbbVie's top-selling drug, Humira, is also approved for treating RA.
Allergan recalls Biocell breast implants, warns physicians not to use them
The company initiated the voluntary recall of textured Biocell breast implants and tissue expanders after it received a warning from the FDA that they were linked to some cases of a type of T-cell lymphoma.
AbbVie to buy Botox maker Allergan for $63B
The companies said the acquisition would diversify AbbVie's portfolio. However, Allergan also faces headwinds from generic competition. A bid to stop a challenge to the patents on its second top-selling drug failed earlier this year.
Drugmakers partner with England’s NHS in $1.3B hepatitis C push
NHS said it hopes to make England the first country to eliminate HCV. The effort will involve finding people living with the virus and providing drugs procured from AbbVie, Gilead and Merck.
AbbVie, Roche’s Venclexta stumbles amid patient deaths in multiple myeloma trial
AbbVie said Tuesday that the FDA had placed a partial clinical hold on all Venclexta studies in myeloma due to a higher rate of deaths in the Phase III BELLINI study.